The EMA Safety Committee (PRAC) concluded that a warning should be added to the product information of the covid-19 Janssen vaccine, and the clot event should be included as a very rare side effect of the vaccine.
Madrid (EUROPA PRESS). -The European Medicines Agency (EMA) Safety Committee concluded on Tuesday that during the injection of the vaccine against covid-19 de Jannsen, although it was confirmed that “may be related to the observation of “rare cases” in “rare cases” related to abnormal blood clots related to low platelets, This may be the cause of thrombosis.
Therefore, just as the AstraZeneca vaccine was used two weeks ago, the EMA Safety Committee (PRAC) concluded that a warning should be added to the product information of the covid-19 Janssen vaccine, and these incidents should be listed as very rare. The role of vaccines.
Last Wednesday, the pharmaceutical company announced that after the drug withdrawal in the United States, due to six cases of thrombosis in people who received more than 600 doses of the vaccine, the company is postponing its presence in Europe after administering more than 6.8 million doses. Launched a vaccine against covid-19.
A few hours later, EMA pointed out that its Safety Committee (PRAC) was also reviewing six cases of thrombosis in the United States after using Janssen’s covid-19 vaccine.
In most cases, the type of thrombus that is combined with a low level of platelets in the blood (thrombocytopenia) is cerebral venous sinus thrombosis (CVST).
Very similar to the case that occurred with the AstraZeneca vaccine, this case is still under investigation since the EMA, although after a preliminary study was conducted two weeks ago, it is recommended that these adverse events be included in the list of “very rare” side effects of the vaccine.
The covid-19 Janssen vaccine is a vaccine to prevent coronavirus disease 2019 (covid-19) in people over 18 years of age. It consists of another virus (from the adenovirus family) that has been modified to contain the gene to produce the protein found in SARS-CoV-2. It stands out from other drugs because it is administered in a single injection, although its effectiveness is lower at 67% compared to it. On March 11, 2021, it received a conditional marketing license from the European Commission.